title: The hypothalamic-pituitary-thyroid axis in critical illness.
abstract: In severe illness, profound changes occur in the hypothalamic-pituitary-thyroid axis. The observed decrease in serum concentration of both thyroid hormones and thyrotropin (TSH) are not compatible with a negative feedback loop and suggest a major change in setpoint regulation of the hypothalamic-pituitary-thyroid axis. This is supported by post mortem studies showing a decreased expression of thyrotropin-releasing hormone in the hypothalamic paraventricular nucleus of patients with a decreased serum T3 level. In critical illness, serum T3 may even become undetectable without giving rise to an elevated concentration of serum TSH. It is currently not clearly established whether this reflects an adaptation of the organism to illness or instead a potentially harmful condition leading to hypothyroidism at tissue level. There is thus a need for randomized clinical trials in critically ill patients to investigate whether they may benefit from a normalization of thyroid hormone concentration. Recent clinical studies in these patients involving the administration of hypothalamic peptides open up new ways of achieving this.
authors.affiliation: Department of Endocrinology and Metabolism, University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Fliers
authors.forename: A
authors.initials: A
authors.lastname: Alkemade
authors.forename: W M
authors.initials: WM
authors.lastname: Wiersinga
mesh_terms: D016638:Critical Illness / Q000628:therapy; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology*; D009479:Neuropeptides / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000175:diagnosis; D013961:Thyroid Gland / Q000503:physiopathology*; D013963:Thyroid Hormones / Q000502:physiology / Q000627:therapeutic use
chemical_list: D009479:Neuropeptides; D013963:Thyroid Hormones